model updat move target price
focu remain celg integr
bottom line updat model compani
incorpor detail confer call follow call
compani also lower target price lower
outer year opdivo estim lower gross margin assumpt
account greater amount growth come eliqui even
tp suggest upsid maintain neutral rate
despit current stock price suggest attract valuat remain
sidelin given on-going close celgen deal question
compani abil integr celgen without experienc disrupt
develop commerci side combin organ
notabl model updat eliqui deliv notabl beat
quarter beat forecast question around
inventori stock rais full year estim product
estim actual come
impact medicar donut hole felt eliqui estim
next sever year go modestli also lower outer year
estim opdivo although still sale given
greater contribut eliqui make compani growth
also lower gross margin assumpt modestli
valuat risk lower tp maintain
neutral rate stand-alone ep estim
remain pro forma ep bristol/celgen
chang tp deriv blend dcf
valuat use wacc termin growth rate
rel valuat base ep main risk
call includ surprisingli positive/neg clinic trial data notabl
greater/less commerci
challeng notabl opdivo/yervoy eliqui
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
bristol-my squibb compani bm engag discoveri
develop licens manufactur market distribut
sale pharmaceut product global basi
price apr rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
opdivo/i-o eliqui yervoy compar current base case
assumpt blue sky valuat base dcf driven
wacc termin valu
grey sky valuat base lower sale opdivo/i-
eliqui yervoy compar current base case assumpt
grey sky valuat base dcf driven wacc
 close
follow
opportun speak member team follow
confer call gain addit clariti dynam certain product
well bake updat expect around fy
summar compani answer question
 impact fail studi opdivo yervoy head neck
shouldnt impact monotherapi
 attempt expand monotherapi opdivo yervoy
 trial previous disclos chanc
us opdivo sale head neck
global opdivo sale head neck
could registr trial
 long-term outlook opdivo
us strong share melanoma renal
lung busi contract expect back year comp
harder
sequenti declin trend opdivo wild card new launch
would drive growth
 outsid us expect contract lung slower process
still launch phase renal adjuv melanoma
 expect price china think around competitor china
 news big market bad news complic market
signific amount competit merck also local
potenti local player get market would disrupt
 label use seen us
still earli day hard see play
 would drive growth yervoy
monotherapi sale yervoy adjuv melanoma
 go forward expect yervoy use combin
monotherapi tie opdivo
expect renal melanoma drive growth
us share opdivo yervoy melanoma
share opdivo yervoy rcc
 drive growth europ opdivo yervoy
cadenc reimburs key rcc adjuv melanoma
began launch renal adjuv melanoma coupl quarter
ahead renal
europ yervoy approv melanoma like us
cannib yervoy opdivo like us
 opportun gastric
focus opdivo chemo combo checkmat
small opportun us patient patient
japan opportun larger patient
 impact donut hole
impact
thing drive impact
product bigger
increas manufactur need cover instead
increas mix medicar patient
contribut coverag gap modest
accru impact patient enter coverag gap balanc
 stock im growth sale growth
littl price favor less price
expect demand drive growth go forward
expect gross net increas eliqui part
 overal anticoagul warfarin factor xa
 sale number sprycel reflect actual demand
favor price/inventori make
 drove emplic step sale
launch combo pomalyst novemb
sale
net incom
revenu
market sell administr
equiti net incom affili
allianc licens incom
total incom expens
provis incom tax
net incom dilut ep
ms sale
revenu
ep continu oper
compani mention price
